8-Bromo-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione Chemical Properties

Melting point:

>255°C (dec.)

Boiling point:

602.9±65.0 °C(Predicted)

Density 

1.55

storage temp. 

under inert gas (nitrogen or Argon) at 2-8°C

solubility 

DMSO (Slightly, Heated, Sonicated), Methanol (Very Slightly, Heated, Sonicated)

pka

2.34±0.50(Predicted)

form 

Solid

color 

White to Pale Yellow

8-Bromo-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione Usage And Synthesis

Uses

8-Bromo-7-(2-butyn-1-yl)-3,7-dihydro-3-methyl-1-[(4-methyl-2-quinazolinyl)methyl]-1H-purine-2,6-dione is an intermediate used to prepare selective inhibitors of dipeptidyl peptidase 4 (DPP4) for potential use in the treatment of type 2 diabetes.

8-Bromo-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione(853029-57-9)Related Product Information

• 8-bromo-7-(but-2-ynyl)-3-methyl-1H-purine-2,6(3H,7H)-dione
• Linagliptin impurity 15
• CPo3604-01
• (1R trans)-2-(3,4-difluorophenyl)cyclopropane amine
• Tetrahydro-2,2-dimethyl-4,7-methano-6H-1,3-dioxolo[4,5-d][1,2]oxazine-6-carboxylic acid phenylmethyl ester
• Canagliflozin
• Cyclopropanamine,2-(3,4-difluorophenyl)-(1R,2S) -(2R,3R)-2,3-dihydroxybutanedioate (1:1)
• Rivaroxaban
• 3-(R)-Piperidinyl PhthaliMide D-(-)-tartaric acid
• Linagliptin
• Hydroxychloroquine O-Sulfate
• Linagliptin Impurity D
• Linagliptin Impurity K
• Linagliptin iMpurity G
• Tert-butyl((3s)-1-(7-(but-2-yn-1-yl)-3-Methyl-1-((4-Methylquinazolin-2-yl)Methyl)-2,6-dioxo-2,3,4,5,6,7-hexahydro-1h-purin-8-yl)piperidin-3-yl)carbaMate
• Linagliptin iMpurity E
• Hydroxychloroquine Sulfate EP Impurity A
• Linagliptin Impurity F